<DOC>
	<DOCNO>NCT00502346</DOCNO>
	<brief_summary>The primary objective study compare effect PM101 I.V . administer immediate intravenous bolus versus placebo systolic blood pressure . Secondary objective include evaluation change baseline heart rate change baseline low value mean arterial pressure diastolic pressure .</brief_summary>
	<brief_title>A Trial Determine Relative Effect PM101 I.V . Versus Placebo Hemodynamics Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<criteria>Be healthy male female 18 55 year age , inclusive . Women childbearing potential must use medically acceptable form birth control duration trial must negative serum pregnancy test screen upon checkin study facility . Have BMI within range 1835 kg/m2 . Be able communicate effectively study personnel . Have significant disease abnormal laboratory value determine medical history , physical examination laboratory evaluation , conduct screen visit admission clinic . Have normal 12lead electrocardiogram , without clinically significant abnormality rate , rhythm conduction ( high grade AV block , bifascicular trifascicular block ) , normal QTc interval ( i.e. , â‰¤ 450 msec male female ) . Be nonsmoker define smoke past 6 month . Be adequately informed nature risk study give write informed consent prior receive study medication . Known hypersensitivity allergy amiodarone , Captisol , Cordarone I.V . excipients . Known hypersensitivity allergy iodine radioopaque dye . Women pregnant breast feeding . A history presence asthma pulmonary disease , thyroid disease ( hypo hyperthyroidism ) , hepatitis liver disease . Any disease condition ( medical surgical ) , opinion investigator , might compromise hematologic , cardiovascular , pulmonary , renal , gastrointestinal , hepatic , central nervous system ; condition may interfere absorption , distribution , metabolism excretion study drug , would place subject increase risk . The presence abnormal laboratory value consider clinically significant . Positive screen Hepatitis B ( HbsAg , Hepatitis B Surface Antigen ) , Hepatitis C ( anti HCV , Hepatitis C Antibody ) , HIV ( antiHIV 1/2 ) . Received investigational drug within period 30 day prior enrollment study . Received drug therapy within 2 week prior administration first dose studyrelated treatment . This exclusion extend 4 week drug know induce inhibit hepatic drug metabolism . However , woman childbearing potential may receive hormonal contraceptive investigator may waive shortterm use medication , specifically prohibit , use occur 5 halflives prior first dose studyrelated treatment . Consumption alcohol within 48 hour prior dose administration inpatient period . A positive urine drug screen include ethanol , cocaine , THC , barbiturates , amphetamine , benzodiazepine , opiate . Any history alcohol abuse , illicit drug use , significant mental illness , physical dependence opioid , history drug abuse addiction . Prior participation Prism Pharmaceuticals amiodarone study . Donation plasma ( 500 mL ) within 7 day prior drug administration . Donation loss whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication follow : 50 mL 499 mL whole blood within 30 day , 499 mL whole blood within 56 day prior drug administration . History severe respiratory failure , circulatory collapse , severe arterial hypotension , heart failure , cardiomyopathy , sinus node disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Pharmacodynamics</keyword>
</DOC>